NYSE$ASH
Ashland Inc · Q4 2024 earnings
Q4 2024 earnings · · Investor relations
Briefing
Ashland's Q4 2024 financial performance reflected a sales increase and significant profitability growth driven by volume recovery and portfolio optimization.
Ashland reported a one percent increase in sales to $522 million for the fourth quarter of fiscal year 2024. Net income rose to $16 million, and adjusted EBITDA increased by 68 percent to $124 million, primarily due to sales and production volume recovery, improved product mix, and deflationary raw materials. The company issued its outlook for full-year fiscal 2025 and provided an update on portfolio optimization.
- Sales increased by one percent to $522 million compared to the prior-year quarter.
- Net income improved to $16 million, up from a net loss of $4 million in the prior-year quarter.
- Adjusted EBITDA increased by 68 percent to $124 million, driven by volume recovery and improved product mix.
- The company repurchased 1.7 million shares and has $620 million remaining under its share repurchase authorization.
Headline financials
Revenue & EPS history
Ashland · Revenue · Quarterly
$522M
Revenue by segment
Ashland · $530M total across 4 segments · Q4 2023
- Life Sciences$203M-4.7%38.3%
- Personal Care$146M-22.3%27.5%
- Specialty Additives$144M-23.0%27.2%
- Intermediates$37M-42.2%7.0%
Forward guidance
For fiscal year 2025, Ashland expects sales to be in the range of $1.90 billion to $2.05 billion, and Adjusted EBITDA to be in the range of $430 million to $470 million.
Tailwinds
- Continued geopolitical and economic uncertainty results in lower overall growth in most regions.
- China’s economy will remain challenged for the fiscal year, especially the property market.
- Increased competitive intensity in China and several export markets result in volume growth being partially offset by additional price erosion.
- +$45 million in improved first-half absorption when compared to inventory actions in fiscal 2024.
- +$20 million in realized cost reduction actions.
Headwinds
- ($30) million from reduced earnings and stranded costs from our nutraceuticals sale and other portfolio optimization actions.
- ($20) million in negative price carryover from fiscal year 2024.
- For Avoca, Ashland exited an unprofitable tolling operation and will sell or close the remaining sclareolide business; ($15) million year-over-year EBITDA erosion.
- ($10) million in variable incentive reset.
- Continued geopolitical and economic uncertainty results in lower overall growth in most regions.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q4 2024
-0.4%
Avg return
Earnings day
-0.7%
Avg return
5 days after
+0.8%
Avg return
30 days after
45%
29 / 64 earnings
Positive
+15.9%
Q1 2024
Best reaction
-10.2%
Q2 2023
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q2 2026 | +8.4% | +6.3% | +17.7% | |
| Q1 2026 | -0.8% | +4.2% | -6.8% | |
| Q4 2025 | -1.0% | -1.3% | +15.5% | |
| Q2 2025 | -9.9% | -11.5% | -9.0% | |
| Q1 2025 | -9.8% | -14.4% | -14.5% | |
| Q4 2024 | -5.0% | -7.3% | -11.2% | |
| Q3 2024 | -3.2% | -6.5% | -7.4% | |
| Q2 2024 | -2.6% | -1.2% | +2.7% | |
| Q1 2024 | +15.9% | +13.4% | +15.9% | |
| Q4 2023 | -4.8% | +0.8% | +7.3% | |
| Q3 2023 | +0.1% | +1.3% | -6.9% | |
| Q2 2023 | -10.2% | -9.5% | -15.0% | |
| Q1 2023 | +1.5% | -1.4% | -3.8% | |
| Q4 2022 | +7.9% | +8.0% | +11.9% | |
| Q3 2022 | -2.5% | -4.3% | +1.5% | |
| Q2 2022 | +4.7% | +3.5% | +4.3% | |
| Q1 2022 | +1.2% | -0.8% | -5.9% | |
| Q4 2021 | +1.4% | +7.4% | +5.3% | |
| Q3 2021 | -3.9% | -3.1% | -2.3% | |
| Q2 2021 | -7.0% | -7.3% | +1.2% | |
| Q1 2021 | +1.3% | +2.3% | +3.0% | |
| Q4 2020 | -2.4% | +3.9% | -2.5% | |
| Q3 2020 | -2.5% | -5.2% | -5.1% | |
| Q2 2020 | -0.1% | +5.3% | +20.8% | |
| Q1 2020 | +1.1% | -1.8% | +0.8% | |
| Q4 2019 | -3.8% | -8.6% | -3.8% | |
| Q3 2019 | +0.0% | -3.5% | -8.7% | |
| Q2 2019 | -5.4% | -4.9% | -5.0% | |
| Q1 2019 | +2.7% | +2.0% | +1.8% | |
| Q4 2018 | +9.0% | +8.5% | +2.6% | |
| Q3 2018 | +2.5% | +3.9% | +2.6% | |
| Q2 2018 | +7.7% | +10.6% | +17.4% | |
| Q1 2018 | +0.3% | +2.0% | -2.2% | |
| Q4 2017 | -3.6% | -3.9% | +2.5% | |
| Q3 2017 | -2.4% | -2.3% | -4.5% | |
| Q2 2017 | -1.4% | -2.5% | +7.6% | |
| Q1 2017 | +2.1% | +2.2% | +4.6% | |
| Q4 2016 | -4.1% | -5.3% | +1.3% | |
| Q3 2016 | -6.4% | -6.7% | -4.3% | |
| Q2 2016 | -0.7% | — | — | |
| Q1 2016 | -1.9% | — | — | |
| Q4 2015 | -0.1% | — | — | |
| Q3 2015 | -3.2% | — | — | |
| Q2 2015 | -1.4% | — | — | |
| Q1 2015 | +1.3% | — | — | |
| Q4 2014 | +2.9% | — | — | |
| Q3 2014 | -5.1% | — | — | |
| Q2 2014 | +4.5% | — | — | |
| Q1 2014 | -1.0% | — | — | |
| Q4 2013 | -5.8% | — | — | |
| Q3 2013 | +0.4% | — | — | |
| Q2 2013 | -0.1% | — | — | |
| Q1 2013 | +6.9% | — | — | |
| Q4 2012 | +0.4% | — | — | |
| Q3 2012 | -0.4% | — | — | |
| Q2 2012 | +1.5% | — | — | |
| Q1 2012 | +1.3% | — | — | |
| Q4 2011 | -4.8% | — | — | |
| Q3 2011 | +4.0% | — | — | |
| Q2 2011 | +0.8% | — | — | |
| Q1 2010 | +3.1% | — | — | |
| Q4 2010 | -1.2% | — | — | |
| Q3 2010 | -5.7% | — | — | |
| Q2 2010 | +2.8% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro